Case Name: E8 PHARMACEUTICALS, LLC and The Massachusetts Institute of Technology, Plaintiffs-Appellants, v. AFFYMETRIX, INC. and Navigenics, Inc., Defendants-Appellees
Court: United States Court of Appeals for the Federal Circuit
Jurisdiction: United States
Decision Date: 2013-11-06
Citations: 538 F. App'x 902
Docket Number: No. 2013-1046
Parties: E8 PHARMACEUTICALS, LLC and The Massachusetts Institute of Technology, Plaintiffs-Appellants, v. AFFYMETRIX, INC. and Navigenics, Inc., Defendants-Appellees.
Judges: 
Reporter: West's Federal Appendix
Volume: 538
Pages: 902–902

Head Matter:
E8 PHARMACEUTICALS, LLC and The Massachusetts Institute of Technology, Plaintiffs-Appellants, v. AFFYMETRIX, INC. and Navigenics, Inc., Defendants-Appellees.
No. 2013-1046.
United States Court of Appeals, Federal Circuit.
Nov. 6, 2013.
John B. Wyss, Wiley Rein LLP, of Washington, DC, argued for plaintiffs-appellants. With him on the brief were James H. Wallace, Jr., Mark A. Pacella, and Gregory R. Lyons.
Peter E. Root, Kaye Scholer LLP, of Palo Alto, CA, argued for defendants-ap-pellees. With him on the brief were Michael J. Malecek, Sean M. Boyle, and Gary Ross Allen.
Before LOURIE, DYK, and O’MALLEY, Circuit Judges.

Opinion:
PER CURIAM.
We affirm the judgment of noninfringement in favor of Affymetrix, Inc. and Navi-genics, Inc. We base our decision solely on our agreement with the district court's construction of the phrase "randomly primed PCR-derived RCG." We do not reach any other issues raised on appeal.
AFFIRMED